These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8040040)

  • 21. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer.
    Pos FJ; Horenblas S; Lebesque J; Moonen L; Schneider C; Sminia P; Bartelink H
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):696-705. PubMed ID: 15183473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of tumor repopulation on radiotherapy planning.
    Wang JZ; Li XA
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiobiological responses for two cell lines following continuous low dose-rate (CLDR) and pulsed dose rate (PDR) brachytherapy.
    Hanisch PH; Furre T; Olsen DR; Pettersen EO
    Acta Oncol; 2007; 46(5):602-11. PubMed ID: 17562436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What hypofractionated protocols should be tested for prostate cancer?
    Fowler JF; Ritter MA; Chappell RJ; Brenner DJ
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1093-104. PubMed ID: 12829147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships.
    Brenner DJ; Hlatky LR; Hahnfeldt PJ; Huang Y; Sachs RK
    Radiat Res; 1998 Jul; 150(1):83-91. PubMed ID: 9650605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving the therapeutic ratio in stereotactic radiosurgery: optimizing treatment protocols based on kinetics of repair of sublethal radiation damage.
    Andisheh B; Belkić D; Mavroidis P; Alahverdi M; Lind BK
    Technol Cancer Res Treat; 2013 Aug; 12(4):349-61. PubMed ID: 23448573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhomogeneous target-dose distributions: a dimension more for optimization?
    De Gersem WR; Derycke S; Colle CO; De Wagter C; De Neve WJ
    Int J Radiat Oncol Biol Phys; 1999 May; 44(2):461-8. PubMed ID: 10760444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans.
    Liang X; Penagaricano J; Zheng D; Morrill S; Zhang X; Corry P; Griffin RJ; Han EY; Hardee M; Ratanatharathom V
    Radiat Oncol; 2016 Jan; 11():10. PubMed ID: 26800883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Why shorter half-times of repair lead to greater damage in pulsed brachytherapy.
    Fowler JF
    Int J Radiat Oncol Biol Phys; 1993 May; 26(2):353-6. PubMed ID: 8491693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulsed brachytherapy: the conditions for no significant loss of therapeutic ratio compared with traditional low dose rate brachytherapy.
    Fowler J; Mount M
    Int J Radiat Oncol Biol Phys; 1992; 23(3):661-9. PubMed ID: 1612968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous, pulsed or single acute irradiation of a transplanted rodent tumour model.
    Sethi T; Dixon B; Flynn A; Ash DV
    Radiother Oncol; 1997 May; 43(2):203-9. PubMed ID: 9192968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
    King CR
    Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of continuous and pulsed low dose rate brachytherapy: biological equivalence in vivo.
    Mason KA; Thames HD; Ochran TG; Ruifrok AC; Janjan N
    Int J Radiat Oncol Biol Phys; 1994 Feb; 28(3):667-71. PubMed ID: 8113110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dosimetric parameters in partial breast irradiation through brachytherapy.
    Gloi A; McCourt S; Buchanan R; Goetller A; Zuge C; Balzoa P; Cooley G
    Med Dosim; 2009; 34(3):207-13. PubMed ID: 19647630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is it necessary to eliminate the posterior dose margin in prostate brachytherapy to achieve an acceptably low risk of late rectal morbidity?
    Waterman FM; Dicker AP
    Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):293-9. PubMed ID: 12909246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of three accelerated partial breast irradiation techniques: treatment effectiveness based upon biological models.
    Bovi J; Qi XS; White J; Li XA
    Radiother Oncol; 2007 Sep; 84(3):226-32. PubMed ID: 17692980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
    Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is SBRT Boost Feasible for PET Positive Lymph Nodes for Cervical Cancer? Evaluation using Tumor Control Probability and QUANTEC Criteria.
    Snyder JE; Willett AB; Sun W; Kim Y
    Pract Radiat Oncol; 2019 Mar; 9(2):e156-e163. PubMed ID: 30415074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations.
    Pötter R; Knocke TH; Fellner C; Baldass M; Reinthaller A; Kucera H
    Cancer Radiother; 2000; 4(2):159-72. PubMed ID: 10812362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Radiobiology in brachytherapy].
    Hennequin C; Mazeron JJ
    Cancer Radiother; 2013 Apr; 17(2):81-4. PubMed ID: 23562380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.